Nonalcoholic fatty liver disease (NAFLD) refers to the entire spectrum of disease, from simple steatosis to NASH to fibrosis/cirrhosis
30% (90 million) people have NAFLD, an abnormally high accumulation of fat within hepatocytes (steatosis)
10% (9 million) NAFLD patients develop inflammation in a condition called non-alcoholic steatohepatitis (NASH), with or without fibrosis
25% (2.5 million) NASH patients develop cirrhosis
200,000 – 500,000 patients at risk to develop hepatocellular carcinoma
This site requires cookies to function properly. Cookies are also used for basic analytics to better serve users. Data are collected anonymously, and not sold or otherwise distributed by the proprietors of this site. By using this site, you consent to the cookies necessary for its basic function. If you would like to customize cookies click here.
Essential cookies are defined as those that are necessary for a website to function correctly, such as maintaining a user's session and supporting the secure transmission of data.
Non-essential cookies in the case of the BioSystics-AP are currently limited to the integration of Google Analytics for the purposes of improving the platform. Examples of the information captured include the user's country of origin, the pages they visit, and the type of device/browser used to do so.